Select Page

Biocon Biologic (BBL), a subsidiary of Biocon announces to enter into a definitive agreement and acquire Viatris biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive cash consideration of about $2 billion on the closing of the transaction and up to $335 million as additional payments.

Read the original article here: